KEQU — Kewaunee Scientific Balance Sheet
0.000.00%
- $123.77m
- $170.63m
- $240.47m
- 77
- 94
- 63
- 93
Annual balance sheet for Kewaunee Scientific, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.21 | 4.43 | 8.08 | 23.3 | 14.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 35 | 54.7 | 46.1 | 45.4 | 62.4 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 60.5 | 91.6 | 87.9 | 96.8 | 118 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 25.3 | 22.7 | 25.6 | 25.1 | 36.1 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 89.4 | 119 | 119 | 135 | 195 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 34.2 | 42.3 | 40.1 | 40.8 | 53.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 48.1 | 83.1 | 81.5 | 80 | 130 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 41.2 | 35.7 | 37.4 | 54.8 | 64.5 |
| Total Liabilities & Shareholders' Equity | 89.4 | 119 | 119 | 135 | 195 |
| Total Common Shares Outstanding |